Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 11/20 | 0.44 |
| ▸ | PPARG | P37231 | 7/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | GHSR | Q92847 | 1/20 | 0.41 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24718280 | 0.83 | EPHX2 (0.53) | EPHX2ACSS2TP53 | |
| SCHEMBL24719111 | 0.83 | EPHX2 (0.47) | EPHX2PPARGACSS2TP53 | |
| SCHEMBL24718421 | 0.82 | TP53 (0.46) | TP53 | |
| SCHEMBL24719126 | 0.82 | EPHX2 (0.42) | EPHX2PPARGACSS2TP53 | |
| SCHEMBL24718389 | 0.81 | TP53 (0.46) | ACSS2TP53 | |
| SCHEMBL24719134 | 0.78 | NPC1 (0.47) | TP53 | |
| SCHEMBL24718622 | 0.78 | EPHX2 (0.46) | EPHX2TP53 | |
| SCHEMBL24718839 | 0.77 | TP53 (0.49) | EPHX2TP53 | |
| SCHEMBL24718637 | 0.77 | TP53 (0.49) | TP53 | |
| SCHEMBL24718827 | 0.77 | TP53 (0.49) | EPHX2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220363633-A1 | SUBSTITUTED PYRROLIDONES AND PIPERIDONES AS SMALL MOLECULE INHIBITORS OF EZH2 AND EED PROTEIN BINDING | UNITED STATES GOVERNMENT | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363633-A1 | SUBSTITUTED PYRROLIDONES AND PIPERIDONES AS SMALL MOLECULE INHIBITORS OF EZH2 AND EED PROTEIN BINDING | EED, EZH2, ELP1 | SMYD3 485/4885EPHX2 1431/4885PPARG 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.